<DOC>
	<DOCNO>NCT00004852</DOCNO>
	<brief_summary>The purpose study look safety effectiveness receive lamivudine ( 3TC ) day versus twice day part anti-HIV drug combination .</brief_summary>
	<brief_title>Safety Effectiveness Lamivudine When Given Once Day Versus Twice Day Combination With Other Anti-HIV Drugs HIV-Infected Adults Who Have Never Received Anti-HIV Drugs</brief_title>
	<detailed_description>Patients randomize receive total dosage 3TC either twice day ( Group 1 ) day ( Group 2 ) combination ZDV EFV 48 week . Viral load measurement perform Weeks 4 , 8 , 12 , 16 , 20 , 24 , every 8 week thereafter .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are 18 year age old . Are HIVpositive . Have viral load ( level HIV blood ) least 400 copies/ml within 21 day study entry . Have CD4 count great 100 cells/mm3 within 21 day study entry . Agree practice abstinence use effective barrier method birth control ( , patient woman , unable child ) . Exclusion Criteria Patients eligible study : Have take antiretroviral ( antiHIV ) agent . Are pregnant breastfeeding . Are unable absorb food trouble take medicine mouth . Abuse alcohol drug extent may make study participation difficult . Are likely able complete 48 week study treatment . Have history pancreatitis ( inflamed pancreas ) hepatitis within last 6 month evidence liver disease . Have receive investigational vaccine within past 3 month receive gene therapy . Have severe medical condition diabetes heart trouble . Have diagnose AIDS . Have radiation therapy chemotherapy within 30 day study entry , except treatment Kaposi 's sarcoma . Are take medication affect immune system within 30 day study entry . Are take medication may interact study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Genotype</keyword>
	<keyword>Phenotype</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>efavirenz</keyword>
</DOC>